David P Nicolau

List of Publications by Year
in descending order

387 papers	7,917 citations	66343 42 h-index	110387 64 g-index
391 all docs	391 docs citations	391 times ranked	5840 citing authors

#	Article	IF	Citations
1	Clinical Pharmacodynamics of Meropenem in Patients with Lower Respiratory Tract Infections. Antimicrobial Agents and Chemotherapy, 2007, 51, 1725-1730.	3.2	254
2	Pharmacokinetic and Pharmacodynamic Properties of Meropenem. Clinical Infectious Diseases, 2008, 47, S32-S40.	5.8	167
3	Carbapenems: a potent class of antibiotics. Expert Opinion on Pharmacotherapy, 2008, 9, 23-37.	1.8	159
4	Population Pharmacokinetic Analysis and Dosing Regimen Optimization of Meropenem in Adult Patients. Journal of Clinical Pharmacology, 2006, 46, 1171-1178.	2.0	143
5	Ceftolozane/tazobactam pharmacokinetic/pharmacodynamicâ€derived dose justification for phase 3 studies in patients with nosocomial pneumonia. Journal of Clinical Pharmacology, 2016, 56, 56-66.	2.0	135
6	Increased 3-gram cefazolin dosing for cesarean delivery prophylaxis in obese women. American Journal of Obstetrics and Gynecology, 2015, 213, 415.e1-415.e8.	1.3	120
7	Population Pharmacokinetics of High-Dose, Prolonged-Infusion Cefepime in Adult Critically Ill Patients with Ventilator-Associated Pneumonia. Antimicrobial Agents and Chemotherapy, 2009, 53, 1476-1481.	3.2	114
8	Clinical Pharmacodynamics of Cefepime in Patients Infected with Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2010, 54, 1111-1116.	3.2	110
9	The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship. Intensive Care Medicine, 2017, 43, 1187-1197.	8.2	103
10	Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. Journal of Antimicrobial Chemotherapy, 2005, 56, 388-395.	3.0	98
11	Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. Journal of Antimicrobial Chemotherapy, 2015, 70, 2862-2869.	3.0	98
12	Human Simulated Studies of Aztreonam and Aztreonam-Avibactam To Evaluate Activity against Challenging Gram-Negative Organisms, Including Metallo-Î²-Lactamase Producers. Antimicrobial Agents and Chemotherapy, 2013, 57, 3299-3306.	3.2	92
13	Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Medicine, 2011, 37, 632-638.	8.2	90
14	Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial. Lancet Infectious Diseases, The, 2020, 20, 330-340.	9.1	88
15	Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling. Journal of Infection and Chemotherapy, 2003, 9, 292-296.	1.7	84
16	Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	80
17	Prolonging Î²-lactam infusion: A review of the rationale and evidence, and guidance for implementation. International Journal of Antimicrobial Agents, 2014, 43, 105-113.	2.5	75
18	Clostridium difficile infection in the elderly: an update on management. Clinical Interventions in Aging, 2017, Volume 12, 1799-1809.	2.9	73

#	Article	IF	Citations
19	Clinical Pharmacodynamics of Antipseudomonal Cephalosporins in Patients with Ventilator-Associated Pneumonia. Antimicrobial Agents and Chemotherapy, 2014, 58, 1359-1364.	3.2	68
20	Carbapenemase-producing Pseudomonas aeruginosa â€“an emerging challenge. Emerging Microbes and Infections, 2022, 11, 811-814.	6.5	68
21	Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	67
22	In Vitro Pharmacodynamics of Polymyxin B and Tigecycline Alone and in Combination against Carbapenem-Resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2014, 58, 874-879.	3.2	65
23	Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy. Antimicrobial Agents and Chemotherapy, 2015, 59, 7743-7752.	3.2	64
24	Pharmacokinetics of dalbavancin in plasma and skin blister fluid. Journal of Antimicrobial Chemotherapy, 2007, 60, 681-684.	3.0	61
25	A guide to therapeutic drug monitoring of Î²â€lactam antibiotics. Pharmacotherapy, 2021, 41, 220-233.	2.6	61
26	Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient. Annals of Intensive Care, 2016, 6, 35.	4.6	59
27	Evaluation of the EDTA-Modified Carbapenem Inactivation Method for Detecting Metallo-Î²-Lactamase-Producing Pseudomonas aeruginosa. Journal of Clinical Microbiology, 2020, 58, .	3.9	58
28	Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence. International Journal of Antimicrobial Agents, 2012, 39, 11-15.	2.5	57
29	Pharmacokinetics of Intravenous Linezolid in Moderately to Morbidly Obese Adults. Antimicrobial Agents and Chemotherapy, 2013, 57, 1144-1149.	3.2	56
30	Bactericidal Activities of Meropenem and Ertapenem against Extended-Spectrum-Î²-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae in a Neutropenic Mouse Thigh Model. Antimicrobial Agents and Chemotherapy, 2007, 51, 1481-1486.	3.2	55
31	Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. Diagnostic Microbiology and Infectious Disease, 2007, 57, 153-161.	1.8	55
32	Efficacies of Ceftazidime-Avibactam and Ceftazidime against Pseudomonas aeruginosa in a Murine Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2014, 58, 1365-1371.	3.2	55
33	In VivoEfficacy of a Human-Simulated Regimen of Ceftaroline Combined with NXL104 against Extended-Spectrum-Î²-Lactamase (ESBL)-Producing and Non-ESBL-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2011, 55, 3220-3225.	3.2	52
34	Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals. Clinical Therapeutics, 2015, 37, 1564-1571.	2.5	52
35	Review of antimicrobial use and considerations in the elderly population. Clinical Interventions in Aging, 2018, Volume 13, 657-667.	2.9	52
36	Augmented Renal Clearance and How to Augment Antibiotic Dosing. Antibiotics, 2020, 9, 393.	3.7	52

#	Article	IF	Citations
37	Continuous and Prolonged Intravenous Î²-Lactam Dosing: Implications for the Clinical Laboratory. Clinical Microbiology Reviews, 2016, 29, 759-772.	13.6	51
38	Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival. Antimicrobial Agents and Chemotherapy, 2016, 60, 1401-1410.	3.2	51
39	Diagnostic and medical needs for therapeutic drug monitoring of antibiotics. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 791-797.	2.9	51
40	Cefepime pharmacodynamics in patients with extended spectrum Î²-lactamase (ESBL) and non-ESBL infections. Journal of Infection, 2007, 54, 463-468.	3.3	49
41	The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 2533-2541.	2.9	48
42	Pharmacodynamic optimization of Î²-lactams in the patient care setting. Critical Care, 2008, 12, S2.	5.8	47
43	Carbapenem-Resistant Enterobacterales, Carbapenem Resistant Organisms, Carbapenemase-Producing Enterobacterales, and Carbapenemase-Producing Organisms: Terminology Past its â€œSell-By Dateâ€•in an Era of New Antibiotics and Regional Carbapenemase Epidemiology. Clinical Infectious Diseases, 2020, 71, 1776-1782.	5.8	47
44	In Vivo Activities of Simulated Human Doses of Cefepime and Cefepime-AAI101 against Multidrug-Resistant Gram-Negative Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2015, 59, 2688-2694.	3.2	44
45	Impact of the New Delhi metallo-beta-lactamase on beta-lactam antibiotics. Infection and Drug Resistance, 2015, 8, 297.	2.7	43
46	Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia. Journal of Antimicrobial Chemotherapy, 2020, 75, 1546-1553.	3.0	43
47	Clinical and economic implications of antimicrobial resistance for the management of community-acquired respiratory tract infections. Journal of Antimicrobial Chemotherapy, 2002, 50, 61-70.	3.0	42
48	In Vivo Efficacy of Humanized Exposures of Ceftazidime-Avibactam in Comparison with Ceftazidime against Contemporary Enterobacteriaceae Isolates. Antimicrobial Agents and Chemotherapy, 2014, 58, 6913-6919.	3.2	42
49	Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens. International Journal of Antimicrobial Agents, 2016, 48, 535-541.	2.5	42
50	Antibacterial Efficacy of Eravacycline In Vivo against Gram-Positive and Gram-Negative Organisms. Antimicrobial Agents and Chemotherapy, 2016, 60, 5001-5005.	3.2	42
51	Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	42
52	Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint. Clinical Infectious Diseases, 2019, 68, 1650-1657.	5.8	42
53	Pharmacodynamic Assessment of Cefprozil against Streptococcus pneumoniae : Implications for Breakpoint Determinations. Antimicrobial Agents and Chemotherapy, 2000, 44, 1291-1295.	3.2	41
54	Ceftolozane/Tazobactam Pharmacokinetics in a Critically Ill Adult Receiving Continuous Renal Replacement Therapy. Pharmacotherapy, 2016, 36, e30-e33.	2.6	41

#	Article	IF	Citations
55	Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model. International Journal of Antimicrobial Agents, 2018, 51, 206-212.	2.5	41
56	Clinical Pharmacokinetics of Newer Cephalosporins. Clinical Pharmacokinetics, 1995, 28, 361-384.	3.5	40
57	In Vivo Efficacy of Meropenem with a Novel Non-Î²-Lactamâ€“Î²-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	40
58	Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals. International Journal of Antimicrobial Agents, 2014, 44, 235-241.	2.5	38
59	Metallo-Î²-lactamase resistance in Enterobacteriaceae is an artefact of currently utilized antimicrobial susceptibility testing methods. Journal of Antimicrobial Chemotherapy, 2020, 75, 997-1005.	3.0	38
60	Pharmacokinetic and Pharmacodynamic Evaluation of Two Dosing Regimens for Piperacillin-Tazobactam. Pharmacotherapy, 2002, 22, 569-577.	2.6	37
61	Cefepime Dosing in the Morbidly Obese Patient Population. Obesity Surgery, 2012, 22, 465-471.	2.1	37
62	Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients. Surgical Infections, 2019, 20, 55-61.	1.4	37
63	Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology. Current Infectious Disease Reports, 2020, 22, 6.	3.0	37
64	Activities of Clarithromycin, Azithromycin, and Ofioxacin in Combination with Liposomal or Unencapsulated Granulocyte-Macrophage Colony-Stimulating Factor against Intramacrophage Mycobacterium avium-Mycobacterium intracellulare. Journal of Infectious Diseases, 1995, 172, 810-816.	4.0	36
65	Use of a bioabsorbable polymer for the delivery of ofloxacin during experimental osteomyelitis treatment. Journal of Orthopaedic Research, 1998, 16, 76-79.	2.3	36
66	Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts. American Journal of Health-System Pharmacy, 2003, 60, 565-568.	1.0	36
67	Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2018, 73, 942-952.	3.0	36
68	Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	36
69	Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope. International Journal of Antimicrobial Agents, 2018, 52, 688-691.	2.5	36
70	Empiric Treatment of Multidrug-ResistantBurkholderia cepaciaLung Exacerbation in a Patient with Cystic Fibrosis: Application of Pharmacodynamic Concepts to Meropenem Therapy. Pharmacotherapy, 2004, 24, 1641-1645.	2.6	35
71	Current challenges in the management of the infected patient. Current Opinion in Infectious Diseases, 2011, 24, S1-S10.	3.1	35
72	Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation. Antimicrobial Agents and Chemotherapy, 2016, 60, 6578-6584.	3.2	35

#	Article	IF	Citations
73	Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration. International Journal of Antimicrobial Agents, 2016, 48, 342-343.	2.5	35
74	Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration. Antimicrobial Agents and Chemotherapy, 2016, 60, 1899-1901.	3.2	35
75	Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant <i>Pseudomonas aeruginosa</i>. Pharmacology, 2018, 101, 278-284.	2.2	35
76	In vitro elution of ofloxacin from a bioabsorbable polymer. Acta Orthopaedica, 1995, 66, 365-368.	1.4	34
77	Therapeutic Options for Diabetic Foot Infections. Journal of the American Podiatric Medical Association, 2010, 100, 52-63.	0.3	34
78	Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis. Diagnostic Microbiology and Infectious Disease, 2015, 83, 53-55.	1.8	34
79	Development of an HPLC Method for the Determination of Ceftolozane/Tazobactam in Biological and Aqueous Matrixes. Journal of Chromatographic Science, 2016, 54, 1037-1040.	1.4	34
80	Unexpected In Vivo Activity of Ceftazidime Alone and in Combination with Avibactam against New Delhi Metallo-Î²-Lactamase-Producing Enterobacteriaceae in a Murine Thigh Infection Model. Antimicrobial Agents and Chemotherapy, 2014, 58, 7007-7009.	3.2	33
81	Efficacy of Humanized Carbapenem Exposures against New Delhi Metallo-Î²-Lactamase (NDM-1)-Producing Enterobacteriaceae in a Murine Infection Model. Antimicrobial Agents and Chemotherapy, 2013, 57, 3936-3940.	3.2	32
82	In VivoEfficacy of Human Simulated Regimens of Carbapenems and Comparator Agents against NDM-1-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2014, 58, 1671-1677.	3.2	32
83	In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible Enterobacteriaceae. Pathogens, 2015, 4, 620-625.	2.8	32
84	Effects of Urine Matrix and pH on the Potency of Delafloxacin and Ciprofloxacin against Urogenic Escherichia coli and Klebsiella pneumoniae. Journal of Urology, 2015, 194, 563-570.	0.4	32
85	Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria. Expert Opinion on Investigational Drugs, 2018, 27, 325-338.	4.1	32
86	Making a Case for Pediatric Antimicrobial Stewardship Programs. Pharmacotherapy, 2015, 35, 1026-1036.	2.6	31
87	An exploratory analysis of the ability of a cefepime trough concentration greater than 22Âmg/L to predict neurotoxicity. Journal of Infection and Chemotherapy, 2016, 22, 78-83.	1.7	31
88	Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections. Therapeutics and Clinical Risk Management, 2016, Volume 12, 1811-1826.	2.0	30
89	In Vitro Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	30
90	Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia. Journal of Antimicrobial Chemotherapy, 2021, 76, 2902-2905.	3.0	30

#	Article	IF	Citations
91	Potentiation of Antibacterial Activity of the MB-1 Siderophore-Monobactam Conjugate Using an Efflux Pump Inhibitor. Antimicrobial Agents and Chemotherapy, 2015, 59, 2439-2442.	3.2	29
92	Epidemiology and economics of adult patients hospitalized with urinary tract infections. Hospital Practice (1995), 2016, 44, 33-40.	1.0	29
93	Development of Daptomycin Susceptibility Breakpoints for Enterococcus faecium and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Institute. Clinical Infectious Diseases, 2020, 70, 1240-1246.	5.8	29
94	Carbapenem-Nonsusceptible Pseudomonas aeruginosa Isolates from Intensive Care Units in the United States: a Potential Role for New Î²-Lactam Combination Agents. Journal of Clinical Microbiology, 2019, 57, .	3.9	29
95	Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004. International Journal of Antimicrobial Agents, 2007, 30, 452-457.	2.5	28
96	Antibiotic Utilization and Opportunities for Stewardship Among Hospitalized Patients With Influenza Respiratory Tract Infection. Infection Control and Hospital Epidemiology, 2016, 37, 583-589.	1.8	27
97	In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	27
98	Comparative In Vivo Antibacterial Activity of Human-Simulated Exposures of Cefiderocol and Ceftazidime against Stenotrophomonas maltophilia in the Murine Thigh Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	27
99	Assessment of Clostridium difficile Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin. Infection Control and Hospital Epidemiology, 2016, 37, 215-218.	1.8	26
100	Pharmacodynamics of carbapenems for the treatment ofPseudomonas aeruginosaventilator-associated pneumonia: associations with clinical outcome and recurrence. Journal of Antimicrobial Chemotherapy, 2016, 71, 2534-2537.	3.0	26
101	In Vivo Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Thigh Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	26
102	Cost comparison of single daily i.v. doses of ceftriaxone versus continuous infusion of cefotaxime. American Journal of Health-System Pharmacy, 1997, 54, 1614-1618.	1.0	25
103	Meropenem Administered as a Prolonged Infusion to Treat Serious Gram-Negative Central Nervous System Infections. Pharmacotherapy, 2004, 24, 803-807.	2.6	25
104	Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis. Journal of Antimicrobial Chemotherapy, 2016, 71, 189-195.	3.0	25
105	Obesity and skin and soft tissue infections: how to optimize antimicrobial usage for prevention and treatment?. Current Opinion in Infectious Diseases, 2017, 30, 180-191.	3.1	25
106	Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	25
107	Efficacy of Humanized Cefiderocol Exposures over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	25
108	Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline. Expert Opinion on Pharmacotherapy, 2009, 10, 1213-1222.	1.8	24

#	Article	IF	Citations
109	In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates. Annals of Clinical Microbiology and Antimicrobials, 2016, 15, 39.	3.8	24
110	Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria. Expert Opinion on Pharmacotherapy, 2018, 19, 397-408.	1.8	24
111	In Vitro Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	24
112	Meropenemâ€“nacubactam activity against AmpC-overproducing and KPC-expressing Pseudomonas aeruginosa in a neutropenic murine lung infection model. International Journal of Antimicrobial Agents, 2020, 55, 105838.	2.5	24
113	Pharmacodynamic Profile of GSK2140944 against Methicillin-Resistant Staphylococcus aureus in a Murine Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2015, 59, 4956-4961.	3.2	23
114	Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 5627-5630.	3.2	23
115	In vivopharmacodynamics of new-generation Î²-lactamase inhibitor taniborbactam (formerly) Tj ETQq1 1 0.784314 rgBT /Overl Journal of Antimicrobial Chemotherapy, 2020, 75, 3601-3610.	3.0	23
116	In vitro synergy of ceftolozane/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2020, 75, 1874-1878.	3.0	23
117	Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance. International Journal of Antimicrobial Agents, 2021, 57, 106299.	2.5	23
118	Pharmacokinetics and Pharmacodynamics of Continuous and Intermittent Ceftazidime during the Treatment of Nosocomial Pneumonia. Clinical Drug Investigation, 1999, 18, 133-139.	2.2	22
119	Pharmacodynamics of antimicrobials: treatment optimisation. Expert Opinion on Drug Metabolism and Toxicology, 2005, 1, 351-361.	3.3	22
120	Eravacycline Pharmacokinetics and Challenges in Defining Humanized Exposure In Vivo. Antimicrobial Agents and Chemotherapy, 2016, 60, 5072-5075.	3.2	22
121	Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance. Expert Review of Clinical Pharmacology, 2016, 9, 459-476.	3.1	22
122	Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery. Journal of Clinical Pharmacology, 2017, 57, 712-719.	2.0	22
123	Use of continuous-infusion ceftolozane/tazobactam for resistant Gram-negative bacterial infections: a retrospective analysis and brief review of the literature. International Journal of Antimicrobial Agents, 2020, 56, 106158.	2.5	22
124	Treatment of Serratia marcescens Meningitis with Prolonged Infusion of Meropenem. Annals of Pharmacotherapy, 2007, 41, 1077-1081.	1.9	21
125	Impact of vancomycin faecal concentrations on clinical and microbiological outcomes in Clostridium difficile infection. International Journal of Antimicrobial Agents, 2015, 46, 205-208.	2.5	21
126	Epidemiology, treatment, and economics of patients presenting to the emergency department for skin and soft tissue infections. Hospital Practice (1995), 2017, 45, 9-15.	1.0	21

#	Article	IF	Citations
127	Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a â€˜Goldilocksâ€™ window. International Journal of Antimicrobial Agents, 2017, 50, 487-490.	2.5	21
128	Use of ceftolozane-tazobactam in a cystic fibrosis patient with multidrug-resistant pseudomonas infection and renal insufficiency. Respiratory Medicine Case Reports, 2018, 23, 8-9.	0.4	21
129	Vancomycin serum concentrations do not adequately predict tissue exposure in diabetic patients with mild to moderate limb infections. Journal of Antimicrobial Chemotherapy, 2015, 70, 2064-2067.	3.0	20
130	Successful Treatment of Multi-Drug Resistant Pseudomonas aeruginosa Bacteremia with the Recommended Renally Adjusted Ceftolozane/Tazobactam Regimen. Infectious Diseases and Therapy, 2016, 5, 73-79.	4.0	20
131	Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model. Journal of Antimicrobial Chemotherapy, 2019, 75, 149-155.	3.0	20
132	In Vivo Pharmacodynamic Profile of Ceftibuten-Clavulanate Combination against Extended-Spectrum-Î²-Lactamase-Producing Enterobacteriaceae in the Murine Thigh Infection Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	20
133	Use of continuous infusion ceftolozaneâ€“tazobactam with therapeutic drug monitoring in a patient with cystic fibrosis. American Journal of Health-System Pharmacy, 2019, 76, 501-504.	1.0	20
134	Discovery and Characterization of a Water-Soluble Prodrug of a Dual Inhibitor of Bacterial DNA Gyrase and Topoisomerase IV. ACS Medicinal Chemistry Letters, 2015, 6, 822-826.	2.8	19
135	Evaluation of Linezolid Pharmacokinetics in Critically Ill Obese Patients with Severe Skin and Soft Tissue Infections. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	19
136	Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750Âmg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. Pulmonary Pharmacology and Therapeutics, 2012, 25, 94-98.	2.6	18
137	In vitro Activity of Ceftolozane/Tazobactam Alone or with an Aminoglycoside Against Multi-Drug-Resistant Pseudomonas aeruginosa from Pediatric Cystic Fibrosis Patients. Infectious Diseases and Therapy, 2017, 6, 129-136.	4.0	18
138	Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic analysis. International Journal of Antimicrobial Agents, 2018, 51, 727-732.	2.5	18
139	Comparative Assessment of Tedizolid Pharmacokinetics and Tissue Penetration between Diabetic Patients with Wound Infections and Healthy Volunteers via In Vivo Microdialysis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	18
140	In Vivo Efficacy of Plazomicin Alone or in Combination with Meropenem or Tigecycline against Enterobacteriaceae Isolates Exhibiting Various Resistance Mechanisms in an Immunocompetent Murine Septicemia Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	18
141	Assessment of the In Vivo Activity of SPR741 in Combination with Azithromycin against Multidrug-Resistant Enterobacteriaceae Isolates in the Neutropenic Murine Thigh Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	18
142	Piperacillin-Tazobactam-Resistant/Third-Generation Cephalosporin-Susceptible Escherichia coli and Klebsiella pneumoniae Isolates: Resistance Mechanisms and In vitro-In vivo Discordance. International Journal of Antimicrobial Agents, 2020, 55, 105885.	2.5	18
143	Population Pharmacokinetics of Continuous Infusion Ceftazidime. Clinical Pharmacokinetics, 1999, 37, 343-350.	3.5	17
144	To Add or Not To Add Polysorbate 80: Impact on Colistin MICs for Clinical Strains of Enterobacteriaceae and Pseudomonas aeruginosa and Quality Controls. Journal of Clinical Microbiology, 2014, 52, 3810-3810.	3.9	17

#	Article	IF	Citations
145	In Vitro Activity of Human-Simulated Epithelial Lining Fluid Exposures of Ceftaroline, Ceftriaxone, and Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2014, 58, 7520-7526.	3.2	17
146	Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis. Clinical Drug Investigation, 2016, 36, 157-168.	2.2	17
147	Comparative In Vivo Efficacies of Tedizolid in Neutropenic versus Immunocompetent Murine Streptococcus pneumoniae Lung Infection Models. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	17
148	Pharmacodynamics of Daptomycin against Enterococcus faecium and Enterococcus faecalis in the Murine Thigh Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	17
149	Defining the potency of amikacin against Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii derived from Chinese hospitals using CLSI and inhalation-based breakpoints. Infection and Drug Resistance, 2018, Volume 11, 783-790.	2.7	17
150	Management of Pediatric Acute Hematogenous Osteomyelitis, Part I: Antimicrobial Stewardship Approach and Review of Therapies for Methicillinâ€Susceptible Staphylococcus aureus, Streptococcus pyogenes, and Kingella kingae. Pharmacotherapy, 2018, 38, 947-966.	2.6	17
151	Pharmacokinetics-pharmacodynamics of Î²-lactamase inhibitors: are we missing the target?. Expert Review of Anti-Infective Therapy, 2019, 17, 571-582.	4.4	17
152	Comparative efficacy of linezolid and vancomycin for endotracheal tube MRSA biofilms from ICU patients. Critical Care, 2019, 23, 251.	5.8	17
153	Variability in Zinc Concentration among Mueller-Hinton Broth Brands: Impact on Antimicrobial Susceptibility Testing of Metallo-Î²-Lactamase-Producing Enterobacteriaceae. Journal of Clinical Microbiology, 2020, 58, .	3.9	17
154	Population Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections (cSSTI). Infectious Diseases and Therapy, 2014, 3, 269-279.	4.0	16
155	Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: Part I gram positive bacteria. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 267-280.	3.3	16
156	Meropenem time above the MIC exposure is predictive of response in cystic fibrosis children with acute pulmonary exacerbations. Diagnostic Microbiology and Infectious Disease, 2018, 91, 294-297.	1.8	16
157	Physical Compatibility of Meropenem and Vaborbactam With Select Intravenous Drugs During Simulated Y-site Administration. Clinical Therapeutics, 2018, 40, 261-269.	2.5	16
158	Efficacy of Human-Simulated Epithelial Lining Fluid Exposure of Meropenem-Nacubactam Combination against Class A Serine Î²-Lactamase-Producing Enterobacteriaceae in the Neutropenic Murine Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	16
159	Activity of Î²-Lactam Antibiotics against Metallo-Î²-Lactamase-Producing Enterobacterales in Animal Infection Models: a Current State of Affairs. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	16
160	Lomefloxacin Clinical Pharmacokinetics. Clinical Pharmacokinetics, 1993, 25, 6-19.	3.5	15
161	Pharmacodynamics of a Novel Des-F(6)-Quinolone, BMS-284756, against Streptococcus pneumoniae in the Thigh Infection Model. Antimicrobial Agents and Chemotherapy, 2003, 47, 1630-1635.	3.2	15
162	Efficacy of Humanized High-Dose Meropenem, Cefepime, and Levofloxacin against Enterobacteriaceae Isolates Producing Verona Integron-Encoded Metallo-Î²-Lactamase (VIM) in a Murine Thigh Infection Model. Antimicrobial Agents and Chemotherapy, 2015, 59, 7145-7147.	3.2	15

#	Article	IF	Citations
163	Transitions of care in the management of acute bacterial skin and skin structure infections: a paradigm shift. Expert Review of Clinical Pharmacology, 2016, 9, 1039-1045.	3.1	15
164	Effect of Body Weight on Cefazolin and Vancomycin Trabecular Bone Concentrations in Patients Undergoing Total Joint Arthroplasty. Surgical Infections, 2016, 17, 71-77.	1.4	15
165	Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. American Journal of Health-System Pharmacy, 2018, 75, 1048-1056.	1.0	15
166	Nebulized Amikacin and Fosfomycin for Severe Pseudomonas aeruginosa Pneumonia. Critical Care Medicine, 2019, 47, e470-e477.	0.9	15
167	Comparative Evaluation of the In Vitro Activities of WCK 5222 (Cefepime-Zidebactam) and Combination Antibiotic Therapies against Carbapenem-Resistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	15
168	Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa. Journal of Medical Microbiology, 2019, 68, 893-897.	1.8	15
169	Use of Oritavancin in Moderate-to-Severe ABSSSI Patients Requiring IV Antibiotics: A U.S. Payer Budget Impact Analysis. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 752-764.	0.9	14
170	Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem. Journal of Antimicrobial Chemotherapy, 2016, 71, 428-437.	3.0	14
171	Pharmacokinetics and Tissue Penetration of Ceftolozane-Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	14
172	Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007). Infectious Diseases and Therapy, 2019, 8, 383-396.	4.0	14
173	Choosing between the New Cephalosporin Antibiotics. Pharmacoeconomics, 1994, 5, 34-39.	3.3	13
174	Pharmacodynamics and tolerability of high-dose, prolonged infusion carbapenems in adults with cystic fibrosis â€“ A review of 3 cases. Respiratory Medicine CME, 2010, 3, 146-149.	0.1	13
175	Impact of Revised Cefepime CLSI Breakpoints on Escherichia coli and Klebsiella pneumoniae Susceptibility and Potential Impact If Applied to Pseudomonas aeruginosa. Journal of Clinical Microbiology, 2015, 53, 1712-1714.	3.9	13
176	A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin. Annals of Clinical Microbiology and Antimicrobials, 2016, 15, 22.	3.8	13
177	Clinafloxacin for Treatment of Burkholderia cenocepacia Infection in a Cystic Fibrosis Patient. Antimicrobial Agents and Chemotherapy, 2016, 60, 1-5.	3.2	13
178	Clinical and economic implications of urinary tract infections. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 377-383.	1.4	13
179	Epidemiology of Bloodstream Infections Caused by Escherichia coli and Klebsiella pneumoniae That Are Piperacillin-Tazobactam-Nonsusceptible but Ceftriaxone-Susceptible. Open Forum Infectious Diseases, 2018, 5, ofy300.	0.9	13
180	In vitro potency of antipseudomonal Î²-lactams against blood and respiratory isolates of P. aeruginosa collected from US hospitals. Journal of Thoracic Disease, 2019, 11, 1896-1902.	1.4	13

#	Article	IF	Citations
181	Efficacy of Humanized Cefiderocol Exposure Is Unaltered by Host Iron Overload in the Thigh Infection Model. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.2	13
182	Development of Neutropenic Murine Models of Iron Overload and Depletion To Study the Efficacy of Siderophore-Antibiotic Conjugates. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.2	13
183	Evaluation of the in vitro activity of WCK 5222 (cefepime/zidebactam) and currently available combination therapies against single- and double-carbapenemase producing Enterobacteriaceae: Expanding the zone of hope. International Journal of Antimicrobial Agents, 2020, 55, 105863.	2.5	13
184	Synergistic Activity of Exebacase (CF-301) in Addition to Daptomycin against Staphylococcus aureus in a Neutropenic Murine Thigh Infection Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	13
185	Evaluation of the Xpert Carba-R NxG Assay for Detection of Carbapenemase Genes in a Global Challenge Set of Pseudomonas aeruginosa Isolates. Journal of Clinical Microbiology, 2020, 58, .	3.9	13
186	The paradoxical in vivo activity of Î²-lactams against metallo-Î²-lactamase-producing Enterobacterales is not restricted to carbapenems. Journal of Antimicrobial Chemotherapy, 2021, 76, 684-691.	3.0	13
187	Influence of Sex on the Pharmacokinetic Interaction of Fleroxacin and Ciprofloxacin with Caffeine. Clinical Pharmacokinetics, 2003, 42, 985-996.	3.5	12
188	Empiric therapy for secondary peritonitis: A pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation. Clinical Therapeutics, 2007, 29, 889-899.	2.5	12
189	Demography and burden of care associated with patients readmitted for urinary tract infection. Journal of Microbiology, Immunology and Infection, 2015, 48, 517-524.	3.1	12
190	In Vitro Activity of Newer and Conventional Antimicrobial Agents, Including Fosfomycin and Colistin, against Selected Gram-Negative Bacilli in Kuwait. Pathogens, 2018, 7, 75.	2.8	12
191	Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. American Journal of Health-System Pharmacy, 2018, 75, e36-e44.	1.0	12
192	Management of Pediatric Acute Hematogenous Osteomyelitis, Part <scp>II</scp>: A Focus on Methicillinâ€Resistant Staphylococcus aureus, Current and Emerging Therapies. Pharmacotherapy, 2018, 38, 1021-1037.	2.6	12
193	In vitro activity of ampicillin and ceftriaxone against ampicillin-susceptible Enterococcus faecium. Journal of Antimicrobial Chemotherapy, 2019, 74, 2269-2273.	3.0	12
194	Development and Application of a Pragmatic Algorithm to Guide Definitive Carbapenemase Testing to Identify Carbapenemase-Producing Pseudomonas aeruginosa. Antibiotics, 2020, 9, 738.	3.7	12
195	Precision medicine for the diagnosis and treatment of carbapenem-resistant Enterobacterales: time to think from a different perspective. Expert Review of Anti-Infective Therapy, 2020, 18, 721-740.	4.4	12
196	Levofloxacin pharmacodynamics against StenotrophomonasÂmaltophilia in a neutropenic murine thigh infection model: implications for susceptibility breakpoint revision. Journal of Antimicrobial Chemotherapy, 2021, 77, 164-168.	3.0	12
197	Optimised cefiderocol exposures in a successfully treated critically ill patient with polymicrobial Stenotrophomonas maltophilia bacteraemia and pneumonia receiving continuous venovenous haemodiafiltration. International Journal of Antimicrobial Agents, 2021, 58, 106395.	2.5	12
198	Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Novel Therapy for Multidrug Resistant Gram Negative Infections in Children. Current Pediatric Reviews, 2018, 14, 97-109.	0.8	12

#	Article	IF	Citations
199	Clinical exposureâ€“response relationship of cefepime/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model. Journal of Antimicrobial Chemotherapy, 2022, 77, 443-447.	3.0	12
200	Minocycline pharmacodynamics against Stenotrophomonas maltophilia in the neutropenic murine infection model: implications for susceptibility breakpoints. Journal of Antimicrobial Chemotherapy, 2022, 77, 1052-1060.	3.0	12
201	Pharmacokinetics of Cefprozil in Plasma and Middle Ear Fluid. Paediatric Drugs, 2007, 9, 119-123.	3.1	11
202	Comparison of In Vivo and In Vitro Pharmacodynamics of a Humanized Regimen of 600 Milligrams of Ceftaroline Fosamil Every 12 Hours against Staphylococcus aureus at Initial Inocula of 10 ⁶ and 10 ⁸ CFU per Milliliter. Antimicrobial Agents and Chemotherapy, 2014, 58, 6931-6933.	3.2	11
203	Clinical pathway for moderate to severe acute bacterial skin and skin structure infections from a US perspective: a roundtable discussion. Hospital Practice (1995), 2016, 44, 183-189.	1.0	11
204	Patient preferences for treatment of acute bacterial skin and skin structure infections in the emergency department. BMC Health Services Research, 2018, 18, 932.	2.2	11
205	Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	11
206	Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration. Open Forum Infectious Diseases, 2021, 8, ofab252.	0.9	11
207	Management of Pneumonia in the Pediatric Critical Care Unit: An Area for Antimicrobial Stewardship. Current Pediatric Reviews, 2017, 13, 49-66.	0.8	11
208	Employing pharmacokinetic and pharmacodynamic principles to optimize antimicrobial treatment in the face of emerging resistance. Brazilian Journal of Microbiology, 2007, 38, 183-193.	2.0	10
209	Assessing the Surrogate Susceptibility of Oxacillin and Cefoxitin for Commonly Utilized Parenteral Agents against Methicillin-Susceptible Staphylococcus aureus: Focus on Ceftriaxone Discordance between Predictive Susceptibility and in Vivo Exposures. Pathogens, 2015, 4, 599-605.	2.8	10
210	Can we improve clinical outcomes in patients with pneumonia treated with antibiotics in the intensive care unit?. Expert Review of Respiratory Medicine, 2016, 10, 907-918.	2.5	10
211	Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: part II Gram-negative bacteria. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 705-714.	3.3	10
212	Ceftolozane-Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	10
213	In vitro investigation of synergy among fosfomycin and parenteral antimicrobials against carbapenemase-producing Enterobacteriaceae. Diagnostic Microbiology and Infectious Disease, 2019, 95, 216-220.	1.8	10
214	Intrapulmonary Pharmacokinetic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients With Pneumonia and Healthy Subjects. Journal of Clinical Pharmacology, 2022, 62, 670-680.	2.0	10
215	Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. International Journal of Antimicrobial Agents, 2015, 45, 512-518.	2.5	9
216	Physical compatibility of ceftolozaneâ€“tazobactam with selected i.v. drugs during simulated Y-site administration. American Journal of Health-System Pharmacy, 2017, 74, e47-e54.	1.0	9

#	Article	IF	Citations
217	Cefazolin potency against methicillin-resistant Staphylococcus aureus: a microbiologic assessment in support of a novel drug delivery system for skin and skin structure infections. Infection and Drug Resistance, 2017, Volume 10, 227-230.	2.7	9
218	Potency of parenteral antimicrobials including ceftolozane/tazobactam against nosocomial respiratory tract pathogens: considerations for empiric and directed therapy. Journal of Thoracic Disease, 2017, 9, 214-221.	1.4	9
219	Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia. International Journal of Antimicrobial Agents, 2019, 54, 346-350.	2.5	9
220	Assessment of Meropenem and Vaborbactam Room Temperature and Refrigerated Stability in Polyvinyl Chloride Bags and Elastomeric Devices. Clinical Therapeutics, 2020, 42, 606-613.	2.5	9
221	Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against Pseudomonas aeruginosa from patients with cystic fibrosis. Annals of Clinical Microbiology and Antimicrobials, 2021, 20, 9.	3.8	9
222	Discrepancy in sustained efficacy and resistance emergence under human-simulated exposure of cefiderocol against Stenotrophomonas maltophilia between in vitro chemostat and in vivo murine infection models. Journal of Antimicrobial Chemotherapy, 2021, 76, 2615-2621.	3.0	9
223	Human-Simulated Antimicrobial Regimens in Animal Models: Transparency and Validation Are Imperative. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	9
224	Clinical use of antimicrobial pharmacodynamic profiles to optimise treatment outcomes in community-acquired bacterial respiratory tract infections: application to telithromycin. Expert Opinion on Pharmacotherapy, 2004, 5, 229-235.	1.8	8
225	Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2177-2181.	2.2	8
226	Validation of a Dosing Strategy for Cefazolin for Surgery Requiring Cardiopulmonary Bypass. Surgical Infections, 2015, 16, 829-832.	1.4	8
227	Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections. Expert Opinion on Investigational Drugs, 2015, 24, 1261-1273.	4.1	8
228	Humanized Exposures of a Î²-Lactam-Î²-Lactamase Inhibitor, Tazobactam, versus Non-Î²-Lactam-Î²-Lactamase Inhibitor, Avibactam, with or without Colistin, against <i>Acinetobacter baumannii</i> in Murine Thigh and Lung Infection Models. Pharmacology, 2018, 101, 255-261.	2.2	8
229	Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clinical Therapeutics, 2019, 41, 2162-2170.	2.5	8
230	In Vitro Pharmacodynamics of a Novel Ceftibuten-Clavulanate Combination Antibiotic against Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	8
231	Pharmacokinetics of Cefazolin and Vancomycin in Infants Undergoing Open-Heart Surgery With Cardiopulmonary Bypass. Anesthesia and Analgesia, 2019, 128, 935-943.	2.2	8
232	Monte Carlo Simulation Methodologies for Î²â€Łactam/Î²â€Łactamase Inhibitor Combinations: Effect on Probability of Target Attainment Assessments. Journal of Clinical Pharmacology, 2020, 60, 172-180.	2.0	8
233	Imipenem/Cilastatin/Relebactam Alone and in Combination againstPseudomonas aeruginosain theIn VitroPharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	8
234	Clinical pharmacokinetics of ceftolozane and tazobactam in an obese patient receiving continuous venovenous haemodiafiltration: A patient case and literature review. Journal of Global Antimicrobial Resistance, 2020, 21, 83-85.	2.2	8

#	Article	IF	Citations
235	Efficacy of human-simulated exposures of meropenem/vaborbactam and meropenem against OXA-48 Î²-lactamase-producing Enterobacterales in the neutropenic murine thigh infection model. Journal of Antimicrobial Chemotherapy, 2021, 76, 184-188.	3.0	8
236	Humanized tissue pharmacodynamics of cefazolin against commonly isolated pathogens in skin and skin structure infections. Journal of Antimicrobial Chemotherapy, 2014, 69, 2443-2447.	3.0	7
237	Detection of Piperacillin-Tazobactam-Resistant/Pan-Î²-Lactam-Susceptible Escherichia coli with Current Automated Susceptibility Test Systems. Infection Control and Hospital Epidemiology, 2017, 38, 379-380.	1.8	7
238	Feasibility of routine synergy testing using antibiotic gradient diffusion strips in the clinical laboratory. Journal of Antimicrobial Chemotherapy, 2018, 73, 2264-2265.	3.0	7
239	A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales. Clinical Therapeutics, 2019, 41, 1453-1462.	2.5	7
240	Comparative efficacy of human-simulated epithelial lining fluid exposures of tedizolid, linezolid and vancomycin in neutropenic and immunocompetent murine models of staphylococcal pneumonia. Journal of Antimicrobial Chemotherapy, 2019, 74, 970-977.	3.0	7
241	In vivo activity of human-simulated regimens of imipenem alone and in combination with relebactam against Pseudomonas aeruginosa in the murine thigh infection model. Journal of Antimicrobial Chemotherapy, 2020, 75, 2197-2205.	3.0	7
242	Pharmacokinetics and Time above the MIC Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO). International Journal of Antimicrobial Agents, 2022, 60, 106603.	2.5	7
243	In vivo translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime/avibactam and meropenem against Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2022, 77, 2803-2808.	3.0	7
244	The Effect of Fleroxacin and Ciprofloxacin on the Pharmacokinetics of Multiple Dose Caffeine. Drugs, 1995, 49, 357-359.	10.9	6
245	Pharmacoeconomics of Pneumocystis carinii Pneumonia in HIV-Infected and HIV-Noninfected Patients. Pharmacoeconomics, 1996, 10, 72-78.	3.3	6
246	Antibacterials for the Prophylaxis and Treatment of Bacterial Endocarditis in Children. Paediatric Drugs, 2001, 3, 703-718.	3.1	6
247	Stability of ertapenem 100 mg/mL in polypropylene syringes stored at 25, 4, and â^'20 Â°C. American Journal of Health-System Pharmacy, 2014, 71, 1480-1484.	1.0	6
248	Physical compatibility of tedizolid phosphate with selected i.v. drugs during simulated Y-site administration. American Journal of Health-System Pharmacy, 2016, 73, 1769-1776.	1.0	6
249	Isolation and quantitation of Clostridium difficile in aqueous and fecal matter using two types of selective media. Journal of Microbiology, Immunology and Infection, 2016, 49, 445-447.	3.1	6
250	Anti-staphylococcal activity resulting from epithelial lining fluid (ELF) concentrations of amikacin inhale administered via the pulmonary drug delivery system. Annals of Clinical Microbiology and Antimicrobials, 2017, 16, 2.	3.8	6
251	Effects of Clinically Meaningful Concentrations of Antipseudomonal Î²-Lactams on Time to Detection and Organism Growth in Blood Culture Bottles. Journal of Clinical Microbiology, 2017, 55, 3502-3512.	3.9	6
252	Inhaled Antimicrobials for Ventilator-Associated Pneumonia: Practical Aspects. Drugs, 2017, 77, 1399-1412.	10.9	6

#	Article	IF	Citations
253	Antibacterial activity of human simulated epithelial lining fluid concentrations of amikacin inhale alone and in combination with meropenem againstAcinetobacter baumannii. Infectious Diseases, 2017, 49, 831-839.	2.8	6
254	Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function. Journal of Pharmacy Practice, 2017, 30, 593-599.	1.0	6
255	Application of the Hartford Hospital Nomogram for Plazomicin Dosing Interval Selection in Patients with Complicated Urinary Tract Infection. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	6
256	Effect of Clinically Meaningful Antibiotic Concentrations on Recovery of Escherichia coli and Klebsiella pneumoniae Isolates from Anaerobic Blood Culture Bottles with and without Antibiotic Binding Resins. Journal of Clinical Microbiology, 2019, 57, .	3.9	6
257	EDTA-modified carbapenem inactivation method (eCIM) for detecting IMP Metallo-Î²-lactamaseâ€“producing Pseudomonas aeruginosa: an assessment of increasing EDTA concentrations. BMC Microbiology, 2020, 20, 220.	3.3	6
258	In Vivo Activity of WCK 4282 (High-Dose Cefepime/Tazobactam) against Serine-Î²-Lactamase-Producing Enterobacterales and Pseudomonas aeruginosa in the Neutropenic Murine Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	6
259	Elevated MICs of Susceptible Anti-Pseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa : Implications for Dose Optimization. Antimicrobial Agents and Chemotherapy, 2021, 65, e0120421.	3.2	6
260	In vivo activity of WCK 4282 (high-dose cefepime/tazobactam) against serine Î²-lactamase-producing Enterobacterales and Pseudomonas aeruginosa in the neutropenic murine thigh infection model. Journal of Antimicrobial Chemotherapy, 2021, 76, 993-1000.	3.0	6
261	In Vitro Time-Kill Studies of Trimethoprim/Sulfamethoxazole against Stenotrophomonas maltophilia versus Escherichia coli Using Cation-Adjusted Mueller-Hinton Broth and ISO-Sensitest Broth. Antimicrobial Agents and Chemotherapy, 2022, 66, aac0216721.	3.2	6
262	Assessment of sustained efficacy and resistance emergence under human-simulated exposure of cefiderocol against Acinetobacter baumannii using in vitro chemostat and in vivo murine infection models. JAC-Antimicrobial Resistance, 2022, 4, dlac047.	2.1	6
263	Lack of Correlation between Bristol Stool Scale and Quantitative Bacterial Load in Clostridium difficile Infection. Infectious Diseases: Research and Treatment, 2015, 8, IDRT.S23079.	1.7	5
264	Evaluation of a disease state management guideline for urinary tract infection. International Journal of Antimicrobial Agents, 2016, 47, 451-456.	2.5	5
265	In VitroPharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus: Considering the Variability in Observed Tissue Exposure. Antimicrobial Agents and Chemotherapy, 2016, 60, 955-961.	3.2	5
266	Poor outcomes of empiric ceftriaxoneÂÂ±Âazithromycin for community-acquired pneumonia caused by methicillin-susceptible Staphylococcus aureus. Internal and Emergency Medicine, 2016, 11, 545-551.	2.0	5
267	Translational Efficacy of Humanized Exposures of Cefepime, Ertapenem, and Levofloxacin against Extended-Spectrum-Î²-Lactamase-Producing Escherichia coli in a Murine Model of Complicated Urinary Tract Infection. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	5
268	Recovery of Gram-Negative Bacteria from Aerobic Blood Culture Bottles Containing Antibiotic Binding Resins after Exposure to Î²-Lactam and Fluoroquinolone Concentrations. Journal of Clinical Microbiology, 2019, 57, .	3.9	5
269	Development of an HPLCâ€“MS/MS method for the determination of ceftolozane/tazobactam in bronchoalveolar lavage fluid. Future Science OA, 2019, 5, FSO352.	1.9	5
270	Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.2	5

#	Article	IF	Citations
271	Is One Sample Enough? Î²-Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	5
272	Development of an HPLC Method for the Determination of Meropenem/Vaborbactam in Biological and Aqueous Matrixes. Journal of Chromatographic Science, 2020, 58, 726-730.	1.4	5
273	Pharmacodynamics of Ceftibuten: An Assessment of an Oral Cephalosporin against Enterobacterales in a Neutropenic Murine Thigh Model. Antibiotics, 2021, 10, 201.	3.7	5
274	Comparative in vivo activity of human-simulated plasma and epithelial lining fluid exposures of WCK 5222 (cefepime/zidebactam) against KPC- and OXA-48-like-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model. Journal of Antimicrobial Chemotherapy, 2021, 76, 2310-2316.	3.0	5
275	Evaluation of a Phenotypic Algorithm to Direct Carbapenemase Testing in Pseudomonas aeruginosa: Validation in a Multicenter German Cohort. Microbial Drug Resistance, 2021, 27, 1243-1248.	2.0	5
276	Omadacycline pharmacokinetics and soft-tissue penetration in diabetic patients with wound infections and healthy volunteers using in vivo microdialysis. Journal of Antimicrobial Chemotherapy, 2022, , .	3.0	5
277	Comparison of clarithromycin and ciprofloxacin therapy for Bacillus anthracis Sterne infection in mice with or without 60Co gamma-photon irradiation. Journal of Medical Microbiology, 2005, 54, 1157-1162.	1.8	4
278	In vitro microdialysis membrane efficiency of broad-spectrum antibiotics in combination and alone. Clinical Pharmacology: Advances and Applications, 2014, 6, 97.	1.2	4
279	An exploratory study to evaluate Clostridium difficile polymerase chain reaction ribotypes and infection outcomes. Infection and Drug Resistance, 2016, Volume 9, 143-148.	2.7	4
280	Tissue penetration and exposure of cefepime in patients with diabetic foot infections. International Journal of Antimicrobial Agents, 2016, 47, 247-248.	2.5	4
281	Variability in Emergency Medicine Provider Decisions on Hospital Admission and Antibiotic Treatment in a Survey Study for Acute Bacterial Skin and Skin Structure Infections: Opportunities for Antimicrobial Stewardship Education. Open Forum Infectious Diseases, 2018, 5, ofy206.	0.9	4
282	Falsely elevated vancomycin-concentration values from enzyme immunoassay leading to treatment failure. American Journal of Health-System Pharmacy, 2019, 77, 9-13.	1.0	4
283	Impact of Intraoperative Cell Salvage on Concentrations of Antibiotics Used for Surgical Prophylaxis. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	4
284	1302. Cefiderocol Population Pharmacokinetics and Probability of Target Attainment in Plasma and Epithelial Lining Fluid in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infections. Open Forum Infectious Diseases, 2020, 7, S665-S665.	0.9	4
285	1311. Intrapulmonary Pharmacokinetics of Cefiderocol in Hospitalized and Ventilated Patients Receiving Standard of Care Antibiotics for Bacterial Pneumonia. Open Forum Infectious Diseases, 2020, 7, S668-S668.	0.9	4
286	Efficacy and Safety of Eravacycline in Obese Patients: A Post Hoc Analysis of Pooled Data From the IGNITE1 and IGNITE4 Clinical Trials. Open Forum Infectious Diseases, 2020, 7, ofaa548.	0.9	4
287	In vivo efficacy of WCK 6777 (ertapenem/zidebactam) against carbapenemase-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model. Journal of Antimicrobial Chemotherapy, 2022, 77, 1931-1937.	3.0	4
288	Pharmacokinetics of Ticlopidine in the Rabbit. Journal of Pharmacy and Pharmacology, 2010, 51, 393-396.	2.4	3

#	Article	IF	Citations
289	In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure. Antimicrobial Agents and Chemotherapy, 2016, 60, 222-228.	3.2	3
290	Physical compatibility of isavuconazonium sulfate with select i.v. drugs during simulated Y-site administration. American Journal of Health-System Pharmacy, 2017, 74, e55-e63.	1.0	3
291	1405. Efficacy of the Human-Simulated Regimen (HSR) of Cefepime (FEP)/VNRX-5133 Combination Against Serine Î²-Lactamase-Producing Gram-negative Bacteria in the Neutropenic Murine Thigh Infection Model. Open Forum Infectious Diseases, 2018, 5, S432-S433.	0.9	3
292	Optimizing Antibiotic Administration for Pneumonia. Clinics in Chest Medicine, 2018, 39, 837-852.	2.1	3
293	Where should antibiotic gradient diffusion strips be crossed to assess synergy? A comparison of the standard method with a novel method using steady-state antimicrobial concentrations. International Journal of Antimicrobial Agents, 2019, 53, 698-702.	2.5	3
294	Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration. BMC Infectious Diseases, 2020, 20, 74.	2.9	3
295	Pharmacokinetics, Tissue Distribution, and Efficacy of VIO-001 (Meropenem/Piperacillin/Tazobactam) for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia in Immunocompetent Rabbits with Chronic Indwelling Vascular Catheters. Antimicrobial Agents and Chemotherapy, 2021, 65, e0116821.	3.2	3
296	Phenotypic/Genotypic Profile of OXA-10-Like-Harboring, Carbapenem-Resistant Pseudomonas aeruginosa: Using Validated Pharmacokinetic/Pharmacodynamic In Vivo Models To Further Evaluate Enzyme Functionality and Clinical Implications. Antimicrobial Agents and Chemotherapy, 2021, 65, e0127421.	3.2	3
297	Evaluation of Metallo-Î²-Lactamase Susceptibility Testing in a Physiologic Medium. Microbiology Spectrum, 2021, 9, e0167021.	3.0	3
298	Treatment with appropriate antibiotic therapy in community-acquired respiratory tract infections. American Journal of Managed Care, 2004, 10, S381-8.	1.1	3
299	Multicenter, Prospective Validation of a Phenotypic Algorithm to Guide Carbapenemase Testing in Carbapenem-Resistant Pseudomonas aeruginosa Using the ERACE-PA Global Surveillance Program. Open Forum Infectious Diseases, 2022, 9, ofab617.	0.9	3
300	Ertapenem Concentrations in Obese Patients Undergoing Surgery. Surgical Infections, 2022, 23, 545-549.	1.4	3
301	Infusion Phlebitis. Clinical Drug Investigation, 1998, 15, 531-535.	2.2	2
302	Bugs versus drugs: What is the pharmacistâ€™s challenge?. American Journal of Health-System Pharmacy, 2008, 65, S2-S3.	1.0	2
303	Reply to â€œDouble-Carbapenem Therapy Not Proven To Be More Active than Carbapenem Monotherapy against KPC-Positive Klebsiella pneumoniaeâ€• Antimicrobial Agents and Chemotherapy, 2012, 56, 4038-4038.	3.2	2
304	Pharmacodynamic profiling of modithromycin: Assessment in a pneumococcal murine pneumonia model. International Journal of Antimicrobial Agents, 2014, 43, 540-546.	2.5	2
305	Defining Extended Spectrum Î²-Lactamases: Implications of Minimum Inhibitory Concentration-Based Screening Versus Clavulanate Confirmation Testing. Infectious Diseases and Therapy, 2015, 4, 513-518.	4.0	2
306	Subcutaneous cefazolin to reduce surgical site infections in a porcine model. Journal of Surgical Research, 2018, 224, 156-159.	1.6	2

#	Article	IF	Citations
307	1368. Assessment of the In Vivo Efficacy of Human-Simulated Epithelial Lining Fluid (ELF) Exposure of Meropenem/Nacubactam (MEM/NAC) Combination Against Î²-Lactamase-Producing Enterobacteriaceae in Neutropenic Lung Infection Model. Open Forum Infectious Diseases, 2018, 5, S419-S419.	0.9	2
308	682. In Vivo Pharmacodynamics of VNRX-7145 in the Neutropenic Murine Thigh Infection Model When Administered in Combination with Humanized Exposures of Twice Daily Ceftibuten (CTB) Against Serine Î²-Lactamase-Producing Enterobacteriaceae (SBL-EB). Open Forum Infectious Diseases, 2019, 6, S311-S311.	0.9	2
309	Single Î²-lactams versus combinations as empiric therapy for infections with Pseudomonas aeruginosa: assessing the in vitro susceptibility. Infectious Diseases, 2020, 52, 33-38.	2.8	2
310	The Ongoing Challenge with NDM-Harboring Enterobacteriaceae in Murine Infection Models. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	2
311	A Novel Dosing Strategy of Ceftolozane/Tazobactam in a Patient Receiving Intermittent Hemodialysis. Open Forum Infectious Diseases, 2021, 8, ofab238.	0.9	2
312	In vitro synergy of ticarcillin/clavulanate in combination with aztreonam and ceftolozane/tazobactam against SPM-1-producing Pseudomonas aeruginosa strains. Diagnostic Microbiology and Infectious Disease, 2021, 100, 115343.	1.8	2
313	Efficacy assessment of lysin CF-296 in addition to daptomycin or vancomycin against Staphylococcus aureus in the murine thigh infection model. Journal of Antimicrobial Chemotherapy, 2021, 76, 2622-2628.	3.0	2
314	Ceftolozane/tazobactam for refractory P. aeruginosa endocarditis: A case report and pharmacokinetic analysis. Journal of Infection and Chemotherapy, 2021, 28, 87-90.	1.7	2
315	Development and characterization of a new swine model of invasive pneumococcal pneumonia. Lab Animal, 2021, 50, 327-335.	0.4	2
316	Impact of Order-Set Modifications and Provider Education Following Guideline Updates on Broad-Spectrum Antibiotic Use in Patients Admitted With Community Acquired Pneumonia. Hospital Pharmacy, 2022, 57, 496-503.	1.0	2
317	Pharmacokinetics of Cefazolin in Patients With Obesity Undergoing Surgery Requiring Cardiopulmonary Bypass. Journal of Cardiothoracic and Vascular Anesthesia, 2022, 36, 2942-2947.	1.3	2
318	Comparison of Zinc Concentrations in the Broth of Commercial Automated Susceptibility Testing Devices (Vitek 2, MicroScan, BD Phoenix, and Sensititre). Microbiology Spectrum, 2022, 10, e0005222.	3.0	2
319	1109. Pharmacokinetics and Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO). Open Forum Infectious Diseases, 2021, 8, S646-S646.	0.9	2
320	Maximizing Outcomes in Respiratory Tract Infections in the Age of Resistance. Pharmacotherapy, 2002, 22, 1S-1S.	2.6	1
321	IV to Oral Conversion Programs for Anti-Infectives in the United States: Prevalence and Characteristics. Hospital Pharmacy, 2004, 39, 1069-1075.	1.0	1
322	Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in a thigh model. International Journal of Antimicrobial Agents, 2014, 44, 508-513.	2.5	1
323	Application of "Precision Medicine" Through the Molecular Characterization of Extensively Drug Resistant (XDR) Klebsiella pneumoniae in a Multivisceral Transplant Candidate. Open Forum Infectious Diseases, 2016, 3, .	0.9	1
324	In vivo efficacy of humanized high dose meropenem and comparators against Pseudomonas aeruginosa isolates producing verona integron-encoded metallo-Î²-lactamase (VIM). Heliyon, 2016, 2, e00121.	3.2	1

#	Article	IF	Citations
325	Pharmacodynamic Target Attainment for Meropenem and Piperacillin/Tazobactam Using a PK/PD-based Dosing Calculator in Critically Ill Patients. Open Forum Infectious Diseases, 2017, 4, S27-S27.	0.9	1
326	1336. Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) Against Carbapenems-Resistant Acinetobacter baumannii (CR-ACBN) in the Neutropenic Murine Thigh Infection Model. Open Forum Infectious Diseases, 2018, 5, S408-S408.	0.9	1
327	Reply to Cheng and Chuang. Clinical Infectious Diseases, 2019, 69, 903-904.	5.8	1
328	1550. PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase (CF-301) in Pre-Clinical Models. Open Forum Infectious Diseases, 2019, 6, S565-S566.	0.9	1
329	Efficacy of Telavancin in Comparison to Linezolid in a Porcine Model of Severe Methicillin-Resistant Staphylococcus aureus Pneumonia. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	1
330	Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	1
331	Comment on: An update on cefepime and its future role in combination with novel Î²-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2021, 76, 3326-3327.	3.0	1
332	Reply to Rennie, â€œZinc Concentration Affects Metallo-Beta-Lactamase Susceptibility Testing of Enterobacterales â€• Journal of Clinical Microbiology, 2021, 59, e0121121.	3.9	1
333	Stability of Ertapenem 100 mg/mL at Room Temperature. Canadian Journal of Hospital Pharmacy, 2016, 69, 256-9.	0.1	1
334	1317. Pharmacokinetics (PK) of Ampicillin-Sulbactam (SAM) during Orthotopic Liver Transplantation (OLT). Open Forum Infectious Diseases, 2020, 7, S670-S670.	0.9	1
335	1103. Minocycline (MIN) Pharmacodynamics (PD) against Stenotrophomonas maltophilia (STM) in a Neutropenic Murine Thigh Infection Model. Open Forum Infectious Diseases, 2021, 8, S643-S643.	0.9	1
336	Murine Model for Measuring Effects of Humanized-Dosing of Antibiotics on the Gut Microbiome. Frontiers in Microbiology, 2022, 13, 813849.	3.5	1
337	1087. Imipenem-Cilastatin-Relebactam (I/R) Pharmacokinetics (PK) in Critically Ill Patients with Augmented Renal Clearance (ARC). Open Forum Infectious Diseases, 2021, 8, S635-S635.	0.9	1
338	Serum bactericidal activity of ceftriaxone plus metronidazole against common intra-abdominal pathogens. American Journal of Health-System Pharmacy, 1994, 51, 1782-1787.	1.0	0
339	Influence of automated screening and confirmation of extended-spectrum Î²-lactamase-producing members of the Enterobacteriaceae on prescribing of antibiotics. Journal of Medical Microbiology, 2008, 57, 1147-1151.	1.8	0
340	Pharmacotherapy of Complicated Urinary Tract and Intra-abdominal Infections with Doripenem. Clinical Medicine Therapeutics, 2009, 1, CMT.S2062.	0.1	0
341	In Vitro Discordance with In Vivo Activity: Humanized Exposures of Ceftazidime-Avibactam (Caz-Avi), Aztreonam (ATM), and Tigecycline (TGC) Alone and in Combination Against New Delhi Metallo-Î²-Lactamase-Producing (NDM) Klebsiella pneumoniae (KP) in a Murine Lung Infection Model. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
342	Simplifying Piperacillin/Tazobactam (TZP) Dosing: Pharmacodynamics (PD) of Utilizing 4.5g Doses for Patients With Normal and Impaired Renal Function. Open Forum Infectious Diseases, 2016, 3, .	0.9	0

#	Article	IF	Citations
343	Disposition and Readmission Rates for Patients Presenting to the Emergency Department with Skin and Soft Tissue Infections. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
344	Human-Simulated Exposure and Pharmacodynamic (PD) Assessment of Tedizolid (TZD) Against Streptococcus pneumoniae in an Immunocompetent Murine Lung Infection Model. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
345	Comparative In Vivo Efficacy of Human-Simulated Exposures of Tedizolid (TZD) in Neutropenic (I-) versus Immunocompetent (I+) Murine Streptococcus pneumoniae Lung Infection Model. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
346	In Vivo Activity of Humanized Exposures of Piperacillin-Tazobactam (TZP) against TZP-Resistant/Pan-Î²-Lactam-Susceptible (TZP-R/PBL-S) Escherichia coli in a Murine Pneumonia Model. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
347	Prevalence and Risk Factors of a Novel Piperacillin/Tazobactam-Nonsusceptible, Î²-Lactam-Pan-Susceptible (TZP-NS/BL-PS) Phenotype in Enterobacteriaceae. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
348	Humanized Exposures of a Î²-Lactam/Î²-Lactamase Inhibitor (BL-BLI), Tazobactam (TZB), Versus a Non-Î²-Lactam/Î²-Lactamase Inhibitor, Avibactam (AVI), With or Without Colistin (CST), Against Acinetobacter baumannii (AB) in Murine Thigh and Lung Infection Models. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
349	Clinical use comparison of a semiautomated PCR with fluorescent ribotyping for typing of Clostridium difficile. Archives of Microbiology, 2017, 199, 317-323.	2.2	0
350	Spatio-temporal Activity of Human-Simulated Exposures of Meropenem (MEM) and Ceftolozane (TOL) on Pseudomonas aeruginosa Biofilms. Open Forum Infectious Diseases, 2017, 4, S294-S294.	0.9	0
351	In Vitro Antibacterial Activity of Ceftolozane/Tazobactam (C/T) Alone and in Combination with other Antimicrobial Agents against Multidrug-Resistant (MDR) Pseudomonas aeruginosa (PSA). Open Forum Infectious Diseases, 2017, 4, S298-S299.	0.9	0
352	1397. Comparative Efficacy of Human-Simulated Epithelial Lining Fluid (ELF) Exposures of Tedizolid (TZD) Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Neutropenic (Iâ^') vs. Immunocompetent (I+) Murine Models of Pneumonia. Open Forum Infectious Diseases, 2018, 5, S430-S430.	0.9	0
353	2175. In vitro Potency of Ceftolozane/Tazobactam and Other Antipseudomonal Î²-Lactams Against P. aeruginosa. Open Forum Infectious Diseases, 2018, 5, S642-S642.	0.9	0
354	2176. Single Î²-Lactams v. Combination Regimens: Assessing the Probability that an Active Agent Would be Selected When Considering Empiric Therapy for P. aeruginosa. Open Forum Infectious Diseases, 2018, 5, S642-S643.	0.9	0
355	2388. Efficacy of Humanized Cefiderocol Exposures Over 72 Hours Against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model. Open Forum Infectious Diseases, 2018, 5, S712-S712.	0.9	0
356	1544. Efficacy of Human-Simulated Cefiderocol Exposure Against Gram-Negative Bacteria in an Iron-Overloaded Murine Thigh Infection Model. Open Forum Infectious Diseases, 2019, 6, S563-S563.	0.9	0
357	Critique of prevention of pneumococcal disease in high risk adults: A pharmacistâ€based assessment of adult immunization protocols in clinical practice. JACCP Journal of the American College of Clinical Pharmacy, 2019, 2, 444-445.	1.0	0
358	1533. Is Cation-Adjusted Muellerâ€“Hinton Broth (CAMHB) Appropriate for Metallo-Î²-lactamase (MBL) Susceptibility Testing? Novel Insights in In Vitroâ€“In Vivo Discordance Among MBL-Producing Enterobacteriaceae. Open Forum Infectious Diseases, 2019, 6, S558-S559.	0.9	0
359	675. Efficacy of Human-Simulated Bronchopulmonary Exposures of Cefepime and Zidebactam (WCK) Tj ETQq1 1 0.784314 rgBT /Ove Pneumonia Model. Open Forum Infectious Diseases, 2019, 6, S308-S308.	0.9	0
360	725. WCK 5222 (Cefepime/Zidebactam): An In Vitro Assessment of Activity Compared with Current Dual-Antibiotic Options Against Multidrug-Resistant Pseudomonas aeruginosa. Open Forum Infectious Diseases, 2019, 6, S325-S325.	0.9	0

#	Article	IF	Citations
361	1553. Human-Simulated Pharmacokinetic Profiles of Cefiderocol and Meropenem Are Conserved in Murine Models of Thigh Infection With or Without Iron Overload. Open Forum Infectious Diseases, 2019, 6, S567-S567.	0.9	0
362	685. An In Vitro Investigation of WCK 5222 (Cefepime/Zidebactam) and Currently Available Combination Antibiotic Regimens Against Enterobacteriaceae That Co-express Serine-Î²-Lactamase (SBL) and Metallo-Î²-Lactamase (MBL) Enzymes. Open Forum Infectious Diseases, 2019, 6, S311-S312.	0.9	0
363	450. Evaluation of Linezolid Pharmacokinetics in Obese Patients with Severe Skin and Soft-Tissue Infections. Open Forum Infectious Diseases, 2019, 6, S221-S221.	0.9	0
364	Bactericidal In Vitro Activity of a Tissue-Achievable Concentration of Cefazolin against Methicillin-Resistant Staphylococcus aureus. Surgical Infections, 2021, 22, 447-449.	1.4	0
365	Optimizing Efficacy in CARTIs: Introduction. Annals of Pharmacotherapy, 2004, 38, S7-S7.	1.9	0
366	What Is the 360-Degree Approach to Defining Success for VAP?. Journal of Managed Care Pharmacy, 2009, 15, 3-4.	2.2	0
367	Intracellular and Extracellular Penetration of Azithromycin into Inflammatory and Noninflammatory Blister Fluid. Antimicrobial Agents and Chemotherapy, 1995, 39, 795-795.	3.2	0
368	Effect of Blood Product Resuscitation on the Pharmacokinetics of Ampicillin-Sulbactam during Orthotopic Liver Transplantation. Surgical Infections, 2021, , .	1.4	0
369	1264. Assessment of In Vivo Efficacy of CF-296 in addition to Vancomycin (VAN) and Daptomycin (DAP) against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model. Open Forum Infectious Diseases, 2020, 7, S648-S649.	0.9	0
370	1308. Ex vivo Impact of Autologous Blood Transfusion (ABT) on Concentrations of Antibiotics used for Surgical Prophylaxis. Open Forum Infectious Diseases, 2020, 7, S667-S667.	0.9	0
371	1245. In Vivo Efficacy of WCK 4282 (High Dose Cefepime [FEP]-Tazobactam [TZB]) Against Î²-Lactamase-Producing (BLP) Gram-Negative Bacteria in a Neutropenic Murine Pneumonia Model. Open Forum Infectious Diseases, 2020, 7, S641-S641.	0.9	0
372	13. Evaluation of Etest for Antibiotic Susceptibility and Minimum Inhibitory Concentration (MIC) Agreement Against pseudomonas Aeruginosa (psa) from Patients with Cystic Fibrosis (CF). Open Forum Infectious Diseases, 2020, 7, S7-S8.	0.9	0
373	656. Development and Application of a Pragmatic Algorithm for the Detection of Carbapenemase-Producing Pseudomonas aeruginosa (CP-PA). Open Forum Infectious Diseases, 2020, 7, S384-S385.	0.9	0
374	1312. Metallo-Î²-lactamase-Producing Enterobacterales (MBL-EB): Is it Time to Rethink Our Assessment Tools?. Open Forum Infectious Diseases, 2020, 7, S668-S668.	0.9	0
375	1602. Comparative Activity of Ceftolozane-Tazobactam (C/T) and Ceftazidime-Avibactam (CZA) against Pseudomonas aeruginosa (PSA) from Patients with Cystic Fibrosis (CF). Open Forum Infectious Diseases, 2020, 7, S797-S797.	0.9	0
376	1244. Assessment of the In Vivo Activity of Human-Simulated Exposure of WCK 4282 (High Dose Cefepime) Tj ETQq0 0 0 rgBT /Overloc Neutropenic Murine Thigh Infection Model. Open Forum Infectious Diseases, 2020, 7, S640-S641.	0.9	0
377	1309. Imipenem/Cilastatin/Relebactam (I/R) Alone and in Combination against Pseudomonas aeruginosa (PSA) in the In Vitro Pharmacodynamic Model. Open Forum Infectious Diseases, 2020, 7, S667-S667.	0.9	0
378	1299. In Vitro-In Vivo Discordance with Î²-lactams against Metallo-Î²-lactamase-Producing Enterobacterales: Implications for Susceptibility Testing. Open Forum Infectious Diseases, 2020, 7, S664-S664.	0.9	0

#	Article	IF	Citations
379	1215. Evaluation of the Carba-R NxG Assay in a Global Challenge Set of Pseudomonas aeruginosa. Open Forum Infectious Diseases, 2020, 7, S629-S629.	0.9	0
380	1296. Efficacy of Human-Simulated Exposures of Meropenem/Vaborbactam (MVB) and Meropenem (MEM) against OXA-48 Î²-lactamase-producing Enterobacterales in the Neutropenic Murine Thigh Infection Model. Open Forum Infectious Diseases, 2020, 7, S663-S663.	0.9	0
381	Pharmacokinetic/Pharmacodynamic Optimization of Hospital-Acquired and Ventilator-Associated Pneumonia: Challenges and Strategies. Seminars in Respiratory and Critical Care Medicine, 2022, , .	2.1	0
382	58. Impact of Order-set Modifications and Provider Education on Broad-Spectrum Antibiotic Use in Patients Admitted with Community Acquired Pneumonia. Open Forum Infectious Diseases, 2021, 8, S147-S148.	0.9	0
383	65. In Vivo Efficacy of Human Simulated Minocycline (MIN) against Stenotrophomonas maltophilia (STM). Open Forum Infectious Diseases, 2021, 8, S44-S44.	0.9	0
384	1241. In Vivo Efficacy of Meropenem Against Metallo-ÃŸ-Lactamase (MBL)-Harboring Pseudomonas aeruginosa and Correlation to In Vitro Susceptibility Upon Addition of EDTA. Open Forum Infectious Diseases, 2021, 8, S710-S710.	0.9	0
385	Evaluation of high-concentration EDTA-modified carbapenemase inactivation method (eCIM) for SPM-producing Pseudomonas aeruginosa. Archives of Microbiology, 2022, 204, 55.	2.2	0
386	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2022, , .	3.0	0
387	In vitro potency of amikacin against carbapenem-resistant Pseudomonas aeruginosa: A target for nebulization strategy?. Brazilian Journal of Infectious Diseases, 2022, 26, 102355.	0.6	0